Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free AIM Stock Alerts

AIM ImmunoTech (AIM) Financials

AIM ImmunoTech logo
$0.25 -0.01 (-1.94%)
Closing price 05/15/2026 04:10 PM Eastern
Extended Trading
$0.26 +0.01 (+2.37%)
As of 05/15/2026 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for AIM ImmunoTech

Annual Income Statements for AIM ImmunoTech

This table shows AIM ImmunoTech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -17 -15 -7.50 -8.26 -10 -14 -14 -19 -19 -29 -17
Consolidated Net Income / (Loss)		 -17 -15 -7.50 -8.26 -9.83 -9.40 -14 -19 -19 -29 -17
Net Income / (Loss) Continuing Operations		 -17 -15 -9.13 -9.05 -9.52 -13 -14 -19 -21 -31 -16
Total Pre-Tax Income 		-18 -16 -12 -9.14 -10 -13 -16 -21 -22 -32 -21
Total Operating Income		 -19 -17 -14 -11 -11 -12 -15 -19 -20 -32 -20
Total Gross Profit		 0.20 0.13 0.09 0.44 0.37 0.17 0.16 0.14 0.14 0.20 0.17
Total Revenue		 0.20 0.13 0.09 0.44 0.37 0.17 0.16 0.14 0.14 0.20 0.17
Operating Revenue		 0.20 0.13 0.09 0.44 0.37 0.17 0.16 0.14 0.14 0.20 0.17
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 19 17 14 12 11 14 15 19 20 32 20
Selling, General & Admin Expense		 9.06 7.15 7.68 6.57 6.20 7.04 8.65 8.67 13 21 14
Research & Development Expense		 8.99 8.04 5.11 4.10 4.78 4.65 5.72 7.67 6.99 11 6.20
Other Operating Expenses / (Income)		 1.25 1.60 1.11 1.18 0.88 0.89 0.81 0.85 0.00 0.04 0.03
Other Special Charges / (Income)		 - - - 0.00 -0.70 1.22 0.00 - -0.00 -0.02 0.00
Total Other Income / (Expense), net		 0.67 0.36 1.81 2.28 0.70 0.83 -0.43 -2.61 -1.64 0.20 -1.14
Interest Expense		 0.01 0.00 0.00 0.14 0.50 0.77 0.53 2.77 - 0.00 0.59
Interest & Investment Income		 0.67 0.36 0.13 - 0.03 0.09 0.22 -0.20 -1.68 0.20 -0.09
Other Income / (Expense), net		 0.01 0.00 1.68 2.42 1.17 1.51 -0.12 0.36 0.04 0.00 -0.46
Other Gains / (Losses), net		 1.13 1.37 2.87 0.09 0.58 0.09 1.19 2.32 0.63 1.07 5.19
Other Adjustments to Consolidated Net Income / (Loss)		 -0.15 -0.32 1.63 0.79 -0.86 -0.91 - - 1.49 1.67 -1.60
Basic Earnings per Share		 ($1.11) ($0.77) ($0.34) ($0.29) ($9.77) ($2.58) ($0.45) ($0.40) ($0.40) ($0.60) ($0.31)
Weighted Average Basic Shares Outstanding		 15.69M 19.68M 21.82M 28.68M 1.00M 3.64M 31.84M 47.34M 48.05M 48.59M 56.02M
Diluted Earnings per Share		 ($1.11) ($0.77) ($0.34) ($0.29) ($9.77) ($2.58) ($0.45) - ($0.40) ($0.60) ($0.31)
Weighted Average Diluted Shares Outstanding		 15.69M 19.68M 21.82M 28.68M 1.00M 3.64M 31.84M 47.34M 48.05M 48.59M 56.02M
Weighted Average Basic & Diluted Shares Outstanding		 15.69M 19.68M 21.82M 28.68M 1.00M 3.64M 31.84M 47.34M 48.41M 49.90M 72.29M

Quarterly Income Statements for AIM ImmunoTech

This table shows AIM ImmunoTech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.39 -4.39 -3.66 -4.91 -7.82 -13 -5.82 -1.84 -3.70 -5.97 -3.71
Consolidated Net Income / (Loss)		 -6.39 -4.39 -3.66 -4.91 -7.82 -13 -5.82 -1.84 -3.70 -5.97 -3.71
Net Income / (Loss) Continuing Operations		 -6.71 -5.55 -3.64 -5.24 -8.17 -14 -5.82 -1.84 -3.70 -4.36 -3.71
Total Pre-Tax Income 		-6.89 -5.59 -3.89 -5.56 -8.47 -14 -5.90 -4.42 -4.42 -6.26 -3.72
Total Operating Income		 -6.52 -5.56 -4.30 -5.46 -8.16 -14 -5.73 -3.69 -4.49 -5.86 -3.62
Total Gross Profit		 0.02 0.06 0.05 0.04 0.05 0.07 0.04 0.05 0.04 0.05 0.02
Total Revenue		 0.02 0.06 0.05 0.04 0.05 0.07 0.04 0.05 0.04 0.05 0.02
Operating Revenue		 0.02 0.06 0.05 0.04 0.05 0.07 0.04 0.05 0.04 0.05 0.02
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.54 5.61 4.37 5.50 8.16 14 5.77 3.74 4.52 5.90 3.64
Selling, General & Admin Expense		 5.17 3.65 2.29 2.55 5.44 11 3.82 2.59 3.08 4.23 2.55
Research & Development Expense		 1.37 2.11 2.05 2.95 2.73 3.20 1.95 1.15 1.44 1.66 1.08
Other Operating Expenses / (Income)		 0.00 -0.15 0.00 0.00 0.03 0.01 0.01 0.01 0.01 0.01 0.01
Total Other Income / (Expense), net		 -0.36 -0.03 0.40 -0.09 -0.31 0.20 -0.16 -0.72 0.07 -0.40 -0.10
Interest Expense		 - - 0.00 0.00 0.00 - 0.07 0.18 0.20 0.13 0.12
Interest & Investment Income		 -0.37 0.09 0.20 -0.09 -0.31 0.40 -0.09 -0.09 0.27 -0.19 0.03
Other Gains / (Losses), net		 0.17 0.04 0.26 0.32 0.29 0.20 0.08 2.58 0.72 - 0.01
Basic Earnings per Share		 ($0.13) ($0.09) ($0.08) ($0.10) ($0.16) ($0.26) ($0.12) ($0.03) ($0.06) ($0.10) ($0.05)
Weighted Average Basic Shares Outstanding		 48.08M 48.05M 48.40M 48.41M 48.64M 48.59M 49.46M 52.84M 57.68M 56.02M 70.33M
Diluted Earnings per Share		 ($0.13) - ($0.08) ($0.10) ($0.16) ($0.26) ($0.12) ($0.03) ($0.06) ($0.10) ($0.05)
Weighted Average Diluted Shares Outstanding		 48.08M 48.05M 48.40M 48.41M 48.64M 48.59M 49.46M 52.84M 57.68M 56.02M 70.33M
Weighted Average Basic & Diluted Shares Outstanding		 48.08M 48.41M 48.41M 48.67M 48.84M 49.90M 51.28M 57.14M 63.71M 72.29M 76.42M

Annual Cash Flow Statements for AIM ImmunoTech

This table details how cash moves in and out of AIM ImmunoTech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.35 -0.04 0.29 -1.00 -1.11 1.66 37 -6.41 -5.04 -22 -3.74
Net Cash From Operating Activities		 -14 -16 -7.38 -7.94 -11 -9.07 -10 -14 -16 -21 -15
Net Cash From Continuing Operating Activities		 -16 -16 -7.38 -7.94 -11 -8.58 -10 -14 -16 -21 -15
Net Income / (Loss) Continuing Operations		 -17 -15 -7.50 -8.26 -9.83 -9.40 -14 -19 -19 -29 -17
Consolidated Net Income / (Loss)		 -17 -15 -7.50 -8.26 -9.83 -9.40 -14 -19 -19 -29 -17
Depreciation Expense		 0.67 0.94 1.12 0.95 0.86 0.74 0.67 0.66 0.04 0.04 0.04
Amortization Expense		 0.48 0.25 0.18 0.10 0.29 0.35 0.18 0.16 0.22 0.20 0.51
Non-Cash Adjustments To Reconcile Net Income		 0.41 0.56 -1.21 -1.86 0.12 0.14 2.61 3.42 2.80 0.05 1.28
Changes in Operating Assets and Liabilities, net		 1.93 -2.57 0.03 1.13 -2.08 -0.53 0.58 0.93 0.28 7.41 0.61
Net Cash From Investing Activities		 2.53 6.35 2.92 2.73 0.09 -6.15 -9.16 -0.63 11 -0.83 4.71
Net Cash From Continuing Investing Activities		 2.53 6.35 2.92 2.73 0.09 -6.15 -9.16 -0.63 11 -0.83 4.71
Purchase of Property, Plant & Equipment		 -0.50 -0.24 -0.16 -0.02 -0.05 -0.07 -0.02 -0.04 -0.09 0.00 -0.02
Acquisitions		 -0.26 -0.25 -0.29 -0.05 -0.08 -0.30 -0.57 -0.59 -0.19 -0.59 -0.54
Purchase of Investments		 - - - - -0.83 -5.78 -19 -23 -2.72 -1.59 -0.36
Sale of Property, Plant & Equipment		 - - - 0.00 1.05 - 0.00 0.25 3.90 0.05 0.00
Sale and/or Maturity of Investments		 3.29 6.84 3.37 2.80 - 0.00 10 22 10 1.30 5.62
Net Cash From Financing Activities		 13 9.66 4.76 4.22 9.44 16 57 8.19 0.08 0.49 6.44
Net Cash From Continuing Financing Activities		 13 9.66 4.76 4.22 9.44 16 57 8.19 0.08 0.49 6.44
Repayment of Debt		 - 0.00 0.00 -0.10 -2.66 -2.55 -4.69 -0.12 - 0.00 -0.25
Issuance of Debt		 - 0.00 0.00 1.90 3.06 3.63 - - - 0.00 2.50
Issuance of Common Equity		 13 9.68 4.74 2.42 5.07 15 61 13 0.08 0.49 4.20

Quarterly Cash Flow Statements for AIM ImmunoTech

This table details how cash moves in and out of AIM ImmunoTech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -4.69 -2.71 -3.66 -2.36 -5.77 -9.83 -2.14 0.26 -2.64 0.79 -0.80
Net Cash From Operating Activities		 -4.97 -6.07 -3.68 -2.16 -5.67 -9.76 -4.82 -3.01 -3.11 -3.96 -2.36
Net Cash From Continuing Operating Activities		 -4.97 -6.07 -3.68 -2.16 -5.67 -9.76 -4.82 -3.01 -3.11 -3.96 -2.36
Net Income / (Loss) Continuing Operations		 -6.39 -4.39 -3.66 -4.91 -7.82 -13 -5.82 -1.84 -3.70 -5.97 -3.71
Consolidated Net Income / (Loss)		 -6.39 -4.39 -3.66 -4.91 -7.82 -13 -5.82 -1.84 -3.70 -5.97 -3.71
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 0.02 0.16 0.04 0.07 0.04 0.05 0.12 0.25 0.02 0.12 0.11
Non-Cash Adjustments To Reconcile Net Income		 1.05 1.03 -0.36 -0.18 0.06 0.54 0.17 0.63 0.10 0.39 0.37
Changes in Operating Assets and Liabilities, net		 0.34 -2.88 0.30 2.85 2.04 2.22 0.71 -2.06 0.47 1.49 0.85
Net Cash From Investing Activities		 0.25 3.36 -0.08 -0.20 -0.34 -0.21 -0.16 0.83 0.33 3.70 0.90
Net Cash From Continuing Investing Activities		 0.25 3.36 -0.08 -0.20 -0.34 -0.21 -0.16 0.83 0.33 3.70 0.90
Acquisitions		 - -0.09 - - -0.17 -0.21 -0.05 - -0.14 -0.12 -0.06
Purchase of Investments		 -0.40 -1.06 -0.71 - -0.44 -0.44 -0.16 - - -0.20 -0.09
Sale and/or Maturity of Investments		 0.37 1.00 0.60 - 0.33 0.38 0.05 1.06 0.49 4.03 1.05
Net Cash From Financing Activities		 0.03 - 0.10 0.01 0.23 0.15 2.83 2.44 0.14 1.04 0.66
Net Cash From Continuing Financing Activities		 0.03 - 0.10 0.01 0.23 0.15 2.83 2.44 0.14 1.04 0.66
Issuance of Debt		 - - 0.00 - - - 2.50 -0.13 0.13 - 0.00
Issuance of Common Equity		 0.03 - 0.10 0.01 0.23 0.15 0.33 2.57 0.00 1.29 0.66

Annual Balance Sheets for AIM ImmunoTech

This table presents AIM ImmunoTech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 29 23 19 14 14 21 65 58 40 19 8.61
Total Current Assets		 17 11 6.94 3.51 3.80 10 40 50 36 15 4.18
Cash & Equivalents		 2.16 2.12 2.41 1.41 0.30 1.47 39 32 27 5.44 1.70
Short-Term Investments		 14 6.80 3.46 0.70 1.53 7.31 0.50 16 7.14 7.63 2.28
Accounts Receivable		 - - 0.00 0.02 1.09 0.82 1.12 1.64 1.68 1.18 0.00
Prepaid Expenses		 0.40 0.34 0.31 0.61 0.88 0.85 0.18 0.30 0.46 0.30 0.20
Plant, Property, & Equipment, net		 4.60 11 9.51 8.59 7.78 7.12 6.47 4.05 0.20 0.13 0.11
Total Noncurrent Assets		 8.33 1.00 2.42 2.12 2.26 3.19 18 3.44 3.97 4.70 4.32
Intangible Assets		 0.86 0.86 0.87 0.86 0.91 1.15 1.50 1.97 1.94 2.31 2.59
Other Noncurrent Operating Assets		 7.47 0.13 1.55 1.26 1.35 2.04 0.93 1.47 2.03 2.39 1.73
Total Liabilities & Shareholders' Equity		 29 23 19 14 14 21 65 58 40 19 8.61
Total Liabilities		 4.44 2.43 3.38 5.50 8.67 7.31 3.29 0.82 2.02 9.15 9.93
Total Current Liabilities		 4.44 2.43 2.44 2.71 5.29 1.13 1.10 0.67 1.36 8.65 9.54
Short-Term Debt		 0.02 0.00 - 0.00 3.61 0.21 0.23 - - 0.00 2.31
Accounts Payable		 2.08 1.21 0.89 0.74 0.68 0.47 0.38 0.20 0.38 6.44 6.38
Accrued Expenses		 2.33 1.22 1.55 1.97 1.01 0.40 0.44 0.44 0.81 1.99 0.61
Other Current Liabilities		 - - - - 0.00 0.04 0.05 0.04 0.18 0.22 0.24
Total Noncurrent Liabilities		 0.00 0.00 0.94 2.80 3.38 6.19 2.19 0.15 0.66 0.50 0.40
Other Noncurrent Operating Liabilities		 - 0.00 0.94 0.96 1.06 4.08 0.31 0.15 0.66 0.50 0.40
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 25 20 15 8.70 5.17 13 61 57 38 10 -1.32
Total Preferred & Common Equity		 25 20 15 8.70 5.17 13 61 57 38 10 -1.32
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.78 0.73 0.72 0.70 0.69 0.00
Total Common Equity		 25 20 15 8.70 5.17 13 61 56 38 9.55 -1.32
Common Stock		 303 313 316 317 324 340 403 417 418 419 426
Retained Earnings		 -278 -293 -301 -309 -319 -328 -342 -361 -381 -410 -427
Other Equity Adjustments		 - - - - - - - - 0.00 0.00 0.00

Quarterly Balance Sheets for AIM ImmunoTech

This table presents AIM ImmunoTech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 51 46 37 34 28 16 16 14 6.25
Total Current Assets		 46 41 33 29 23 11 10 7.57 2.58
Cash & Equivalents		 34 30 23 21 15 3.30 3.55 0.92 0.90
Short-Term Investments		 7.32 6.99 7.45 7.36 7.17 7.65 6.51 6.29 1.35
Accounts Receivable		 0.00 0.00 1.76 0.03 0.05 0.00 0.00 0.00 0.02
Prepaid Expenses		 0.37 0.81 0.55 0.44 0.26 0.36 0.30 0.37 0.32
Plant, Property, & Equipment, net		 0.13 0.12 0.16 0.15 0.14 0.12 0.11 0.12 0.10
Total Noncurrent Assets		 4.71 5.02 4.15 4.60 4.98 4.77 5.25 5.90 3.57
Intangible Assets		 2.01 2.01 1.90 2.04 2.15 2.31 2.49 2.53 2.27
Other Noncurrent Operating Assets		 2.70 3.00 2.25 2.57 2.83 2.45 2.75 3.37 1.30
Total Liabilities & Shareholders' Equity		 51 46 37 34 28 16 16 14 6.25
Total Liabilities		 2.10 3.59 2.47 3.48 5.26 11 9.61 11 10
Total Current Liabilities		 1.37 2.90 1.84 2.89 4.72 9.88 8.84 10 9.77
Short-Term Debt		 - - - - - 1.62 2.35 2.59 1.95
Accounts Payable		 0.71 0.96 0.96 2.15 2.79 6.57 5.46 6.26 6.94
Accrued Expenses		 0.50 1.77 0.70 0.53 1.72 1.45 0.80 1.01 0.64
Other Current Liabilities		 0.15 0.17 0.18 0.21 0.21 0.24 0.23 0.23 0.23
Total Noncurrent Liabilities		 0.74 0.70 0.64 0.60 0.54 1.49 0.77 0.58 0.34
Other Noncurrent Operating Liabilities		 0.74 0.70 0.64 0.60 0.54 0.54 0.49 0.44 0.34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 49 43 35 30 23 4.83 6.10 2.91 -3.86
Total Preferred & Common Equity		 49 43 35 30 23 4.83 6.10 2.91 -3.86
Preferred Stock		 0.71 0.71 0.69 0.69 0.69 0.69 0.00 0.00 0.00
Total Common Equity		 48 42 34 29 22 4.14 6.10 2.91 -3.86
Common Stock		 418 418 419 419 419 419 423 424 427
Retained Earnings		 -370 -376 -384 -389 -397 -415 -417 -421 -431
Other Equity Adjustments		 - - - - 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for AIM ImmunoTech

This table displays calculated financial ratios and metrics derived from AIM ImmunoTech's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 31.33% -32.49% -30.83% 375.00% -16.02% -53.68% -4.12% -17.18% 4.44% 43.26% -15.84%
EBITDA Growth		 -6.68% 13.84% 29.99% 26.54% -15.58% -7.21% -46.45% -22.35% -11.20% -61.36% 37.87%
EBIT Growth		 -7.91% 12.76% 27.17% 25.79% -14.80% -5.83% -39.71% -20.96% -7.64% -60.48% 36.61%
NOPAT Growth		 -11.25% 12.82% 17.09% 17.30% -0.70% -8.24% -21.77% -24.33% -5.76% -60.20% 38.05%
Net Income Growth		 -7.55% 12.72% 50.74% -10.09% -18.99% 4.30% -53.13% -32.83% -1.66% -48.94% 40.20%
EPS Growth		 -7.55% 12.72% 55.84% 14.71% -18.99% 73.59% 82.56% 0.00% 0.00% -50.00% 48.33%
Operating Cash Flow Growth		 17.38% -14.96% 54.03% -7.60% -33.99% 14.78% -14.35% -34.69% -15.35% -32.03% 29.99%
Free Cash Flow Firm Growth		 50.17% -27.61% 44.85% 13.26% -30.89% 27.81% -97.04% -1.02% 24.75% -58.40% 10.13%
Invested Capital Growth		 -20.09% 28.53% -15.98% -12.45% 10.00% -24.71% 29.22% -4.56% -50.32% -166.29% -5.50%
Revenue Q/Q Growth		 2.07% -8.90% -10.68% 130.00% -5.90% -49.25% -16.84% 7.14% 4.44% 4.12% -10.53%
EBITDA Q/Q Growth		 -11.57% 16.14% -13.35% 13.70% 4.27% -8.98% -16.19% -12.80% 6.67% -37.47% 29.76%
EBIT Q/Q Growth		 -10.86% 14.58% -11.37% 12.94% 3.99% -7.37% -15.68% -11.94% 6.69% -36.43% 29.01%
NOPAT Q/Q Growth		 -6.47% 9.41% -9.89% 10.17% 1.14% -3.55% -15.59% -14.00% 8.67% -36.00% 29.18%
Net Income Q/Q Growth		 -7.79% 7.97% 20.75% -11.02% 3.65% 5.68% -24.79% -11.22% 6.97% -39.41% 27.62%
EPS Q/Q Growth		 -7.79% 7.97% 20.93% -16.00% 3.65% 44.28% -12.50% 0.00% 0.00% 0.00% 34.04%
Operating Cash Flow Q/Q Growth		 -5.90% 4.29% 14.11% 14.46% -18.47% 1.41% -5.76% -26.11% -2.05% -20.99% 28.05%
Free Cash Flow Firm Q/Q Growth		 39.94% 3.40% -18.34% 28.33% -22.58% 6.49% -12.89% -14.49% 25.08% -43.00% 23.19%
Invested Capital Q/Q Growth		 -0.54% 6.15% 11.69% -8.40% 11.51% 3.15% 2.57% 2.66% -28.10% -1,758.48% -92.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -9,108.12% -11,624.06% -11,765.22% -1,819.45% -2,504.09% -5,795.88% -8,852.76% -13,077.78% -13,923.40% -15,682.18% -11,578.24%
Operating Margin		 -9,694.92% -12,518.80% -15,004.35% -2,612.36% -3,132.43% -7,319.41% -9,295.71% -13,954.07% -14,129.79% -15,800.00% -11,630.59%
EBIT Margin		 -9,687.82% -12,518.80% -13,181.52% -2,059.27% -2,814.99% -6,431.18% -9,371.17% -13,686.67% -14,104.96% -15,800.00% -11,900.00%
Profit (Net Income) Margin		 -8,857.87% -11,451.13% -8,154.35% -1,889.93% -2,677.66% -5,531.76% -8,834.36% -14,168.15% -13,790.78% -14,337.62% -10,188.24%
Tax Burden Percent		 94.68% 93.50% 62.53% 90.38% 97.26% 73.45% 92.39% 89.19% 90.16% 91.32% 82.84%
Interest Burden Percent		 96.57% 97.83% 98.94% 101.54% 97.80% 117.10% 102.04% 116.07% 108.44% 99.37% 103.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -133.17% -114.38% -91.63% -88.49% -90.90% -107.16% -132.55% -149.57% -216.40% -3,098.64% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -109.33% -85.77% -120.87% -79.77% -183.89% -48.36% -119.63% -137.75% -203.07% -3,070.62% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 68.90% 47.25% 49.80% 20.24% -50.73% 6.13% 94.01% 117.20% 175.62% 2,979.71% 0.00%
Return on Equity (ROE)		 -64.27% -67.13% -41.83% -68.25% -141.63% -101.03% -38.54% -32.37% -40.79% -118.94% -388.69%
Cash Return on Invested Capital (CROIC)		 -110.84% -139.34% -74.25% -75.21% -100.43% -78.96% -158.04% -144.91% -149.17% 0.00% 0.00%
Operating Return on Assets (OROA)		 -62.26% -63.74% -58.20% -54.41% -73.66% -63.20% -35.80% -30.22% -40.51% -106.62% -144.56%
Return on Assets (ROA)		 -56.93% -58.30% -36.00% -49.93% -70.06% -54.36% -33.75% -31.28% -39.61% -96.75% -123.76%
Return on Common Equity (ROCE)		 -64.27% -67.13% -41.83% -68.25% -141.63% -96.81% -37.76% -31.97% -40.18% -115.55% -358.64%
Return on Equity Simple (ROE_SIMPLE)		 -69.79% -74.76% -48.41% -94.90% -189.93% -69.96% -23.49% -33.63% -50.55% -283.00% 1,310.14%
Net Operating Profit after Tax (NOPAT)		 -13 -12 -9.66 -7.99 -8.05 -8.71 -11 -13 -14 -22 -14
NOPAT Margin		 -6,786.45% -8,763.16% -10,503.04% -1,828.65% -2,192.70% -5,123.59% -6,506.99% -9,767.85% -9,890.85% -11,060.00% -8,141.41%
Net Nonoperating Expense Percent (NNEP)		 -23.85% -28.61% 29.25% -8.72% 92.99% -58.81% -12.92% -11.82% -13.34% -28.02% -47.21%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -218.30% -1,405.12%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 4,597.46% 5,373.68% 8,348.91% 1,503.89% 1,689.65% 4,140.59% 5,309.20% 6,423.70% 9,272.34% 10,463.86% 8,067.06%
R&D to Revenue		 4,562.44% 6,043.61% 5,551.09% 937.76% 1,301.91% 2,735.88% 3,509.20% 5,682.96% 4,957.45% 5,415.35% 3,645.29%
Operating Expenses to Revenue		 9,794.92% 12,618.80% 15,104.35% 2,712.36% 3,042.51% 8,117.65% 9,395.71% 14,054.07% 14,227.66% 15,891.09% 11,730.59%
Earnings before Interest and Taxes (EBIT)		 -19 -17 -12 -9.00 -10 -11 -15 -18 -20 -32 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -15 -11 -7.95 -9.19 -9.85 -14 -18 -20 -32 -20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.00 0.98 1.07 1.26 1.69 0.36 1.20 0.78 0.40 2.25 0.00
Price to Tangible Book Value (P/TBV)		 2.07 1.02 1.14 1.40 2.05 0.39 1.23 0.81 0.42 2.97 0.00
Price to Revenue (P/Rev)		 253.84 149.81 180.74 25.15 23.77 26.44 446.80 326.08 106.36 106.36 74.20
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.80 0.96 1.12 1.27 1.38 0.00 2.36 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 172.19 82.83 116.96 24.52 34.94 0.00 130.61 0.00 0.00 45.07 64.38
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.21 1.15 0.17 0.03 0.00 0.00 0.00 -1.75
Long-Term Debt to Equity		 0.00 0.00 0.00 0.21 0.45 0.16 0.03 0.00 0.00 0.00 0.00
Financial Leverage		 -0.63 -0.55 -0.41 -0.25 0.28 -0.13 -0.79 -0.85 -0.86 -0.97 -1.65
Leverage Ratio		 1.13 1.15 1.16 1.37 2.02 1.86 1.14 1.03 1.03 1.23 3.14
Compound Leverage Factor		 1.09 1.13 1.15 1.39 1.98 2.18 1.17 1.20 1.12 1.22 3.25
Debt to Total Capital		 0.09% 0.00% 0.00% 17.41% 53.38% 14.71% 3.32% 0.00% 0.00% 0.00% 234.21%
Short-Term Debt to Total Capital		 0.09% 0.00% 0.00% 0.00% 32.50% 1.36% 0.36% 0.00% 0.00% 0.00% 234.21%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 17.41% 20.88% 13.35% 2.96% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.94% 1.15% 1.26% 1.81% 6.73% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.91% 100.00% 100.00% 82.59% 46.62% 80.36% 95.52% 98.74% 98.19% 93.27% -134.21%
Debt to EBITDA		 0.00 0.00 0.00 -0.23 -0.64 -0.24 -0.15 0.00 0.00 0.00 -0.12
Net Debt to EBITDA		 0.90 0.58 0.00 0.03 -0.45 0.66 3.62 0.00 0.00 0.00 0.08
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.23 -0.25 -0.21 -0.13 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.23 -0.74 -0.27 -0.20 0.00 0.00 0.00 -0.17
Net Debt to NOPAT		 1.20 0.76 0.00 0.03 -0.51 0.74 4.93 0.00 0.00 0.00 0.12
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.23 -0.29 -0.24 -0.18 0.00 0.00 0.00 0.00
Altman Z-Score		 -8.09 -15.05 -21.16 -31.22 -34.18 -22.92 5.82 23.43 -9.29 -33.23 -77.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 4.18% 2.02% 1.22% 1.48% 2.84% 7.73%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.72 4.34 2.85 1.29 0.72 9.27 36.58 74.61 26.69 1.68 0.44
Quick Ratio		 3.63 3.66 2.41 0.79 0.55 8.52 36.41 74.16 26.35 1.65 0.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -14 -7.83 -6.79 -8.89 -6.42 -13 -13 -9.61 -15 -14
Operating Cash Flow to CapEx		 -2,770.63% -6,688.75% -4,612.50% -39,705.00% 0.00% -13,333.82% -47,127.27% 0.00% 0.00% 0.00% -82,711.11%
Free Cash Flow to Firm to Interest Expense		 -1,011.57 -4,733.00 0.00 -48.86 -17.71 -8.31 -23.86 -4.62 0.00 0.00 -23.39
Operating Cash Flow to Interest Expense		 -1,269.45 -5,351.00 0.00 -57.13 -21.20 -11.74 -19.56 -5.05 0.00 0.00 -25.45
Operating Cash Flow Less CapEx to Interest Expense		 -1,315.27 -5,431.00 0.00 -57.27 -19.21 -11.83 -19.60 -4.97 0.00 0.00 -25.48
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.00 0.03 0.03 0.01 0.00 0.00 0.00 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.66 0.18 0.17 0.10 0.09 0.14 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.04 0.02 0.01 0.05 0.04 0.02 0.02 0.03 0.07 1.25 1.45
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 555.95 2,054.74 2,176.56 3,737.87 4,293.28 2,583.91 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 555.95 2,054.74 2,176.56 3,737.87 4,293.28 2,583.91 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 8.92 11 9.63 8.43 9.27 6.98 9.02 8.61 4.28 -2.84 -2.99
Invested Capital Turnover		 0.02 0.01 0.01 0.05 0.04 0.02 0.02 0.02 0.02 0.28 -0.06
Increase / (Decrease) in Invested Capital		 -2.24 2.54 -1.83 -1.20 0.84 -2.29 2.04 -0.41 -4.33 -7.11 -0.16
Enterprise Value (EV)		 34 11 11 11 13 -1.19 21 -3.53 -18 9.10 11
Market Capitalization		 50 20 17 11 8.72 4.50 73 44 15 21 13
Book Value per Share		 $0.13 $0.08 $0.64 $0.27 $0.11 $1.53 $1.49 $1.17 $0.79 $0.20 ($0.02)
Tangible Book Value per Share		 $0.12 $0.08 $0.61 $0.25 $0.09 $1.39 $1.45 $1.13 $0.75 $0.15 ($0.06)
Total Capital		 25 20 15 11 11 16 63 57 38 10 0.99
Total Debt		 0.02 0.00 0.00 1.84 5.93 2.32 2.11 0.00 0.00 0.00 2.31
Total Long-Term Debt		 0.00 0.00 0.00 1.84 2.32 2.10 1.88 0.00 0.00 0.00 0.00
Net Debt		 -16 -8.91 -5.87 -0.27 4.10 -6.46 -52 -48 -34 -13 -1.67
Capital Expenditures (CapEx)		 0.50 0.24 0.16 0.02 -1.00 0.07 0.02 -0.20 -3.81 -0.05 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.02 -0.77 -1.36 -1.31 0.29 0.76 0.44 1.27 0.77 -7.17 -7.03
Debt-free Net Working Capital (DFNWC)		 12 8.14 4.51 0.80 2.11 9.53 39 50 35 5.90 -3.05
Net Working Capital (NWC)		 12 8.14 4.51 0.80 -1.49 9.32 39 50 35 5.90 -5.36
Net Nonoperating Expense (NNE)		 4.08 3.58 -2.16 0.27 1.78 0.69 3.79 5.94 5.50 6.62 3.48
Net Nonoperating Obligations (NNO)		 -16 -8.91 -5.87 -0.27 4.10 -6.46 -52 -48 -34 -13 -1.67
Total Depreciation and Amortization (D&A)		 1.14 1.19 1.30 1.05 1.14 1.08 0.85 0.82 0.26 0.24 0.55
Debt-free, Cash-free Net Working Capital to Revenue		 -2,038.07% -579.70% -1,480.43% -299.54% 78.75% 444.12% 267.48% 942.22% 546.10% -3,547.52% -4,134.71%
Debt-free Net Working Capital to Revenue		 6,138.58% 6,119.55% 4,897.83% 182.61% 576.02% 5,607.65% 24,195.09% 36,696.30% 24,794.33% 2,922.77% -1,795.29%
Net Working Capital to Revenue		 6,127.41% 6,118.80% 4,897.83% 182.61% -406.81% 5,481.76% 24,053.99% 36,696.30% 24,794.33% 2,922.77% -3,152.35%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($47.52) ($31.68) ($14.96) ($12.76) ($9.68) ($2.62) ($0.45) ($0.40) ($0.40) ($0.60) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 407.38K 468.89K 595.16K 857.16K 1.42M 27.63M 47.82M 47.99M 48.05M 48.59M 56.02M
Adjusted Diluted Earnings per Share		 ($47.52) ($31.68) ($14.96) ($12.76) ($9.68) ($2.62) ($0.45) ($0.40) $0.00 ($0.60) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 407.38K 468.89K 595.16K 857.16K 1.42M 27.63M 47.82M 47.99M 48.41M 48.59M 56.02M
Adjusted Basic & Diluted Earnings per Share		 ($47.52) ($31.68) ($14.96) ($12.76) ($9.68) ($2.62) ($0.45) ($0.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 356.61K 447.26K 495.87K 651.73K 1.00M 3.64M 31.84M 47.34M 48.41M 49.90M 72.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -12 -9.66 -7.99 -8.54 -7.86 -11 -12 -14 -22 -14
Normalized NOPAT Margin		 -6,786.45% -8,763.16% -10,503.04% -1,828.65% -2,325.64% -4,622.47% -6,449.02% -8,845.41% -9,892.34% -11,066.24% -8,141.41%
Pre Tax Income Margin		 -9,355.84% -12,247.37% -13,041.30% -2,091.08% -2,753.13% -7,531.18% -9,561.96% -15,885.93% -15,295.74% -15,700.99% -12,298.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1,735.00 -5,550.00 0.00 -64.74 -20.58 -14.16 -28.82 -6.68 0.00 0.00 -34.58
NOPAT to Interest Expense		 -1,215.39 -3,885.00 0.00 -57.49 -16.03 -11.28 -20.01 -4.76 0.00 0.00 -23.66
EBIT Less CapEx to Interest Expense		 -1,780.82 -5,630.00 0.00 -64.88 -18.59 -14.25 -28.86 -6.60 0.00 0.00 -34.61
NOPAT Less CapEx to Interest Expense		 -1,261.21 -3,965.00 0.00 -57.63 -14.04 -11.37 -20.05 -4.69 0.00 0.00 -23.69
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AIM ImmunoTech

This table displays calculated financial ratios and metrics derived from AIM ImmunoTech's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -36.36% 11.76% 48.48% 40.00% 119.05% 14.04% -18.37% 19.05% -23.91% -30.77% -60.00%
EBITDA Growth		 -75.36% 20.30% -32.88% -17.39% -24.83% -156.74% -38.38% 27.63% 44.92% 58.97% 37.59%
EBIT Growth		 -68.13% 20.08% -33.16% -18.38% -25.11% -150.08% -39.99% 23.97% 44.97% 58.20% 36.89%
NOPAT Growth		 -65.97% 25.40% -36.26% -16.32% -25.09% -152.08% -33.50% 32.36% 44.97% 58.19% 36.89%
Net Income Growth		 -66.88% 24.92% 4.16% -1.20% -22.41% -186.53% -58.89% 62.60% 52.66% 52.55% 36.31%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -23.08% 0.00% -50.00% 70.00% 62.50% 61.54% 58.33%
Operating Cash Flow Growth		 -43.71% -5.64% -33.43% 6.70% -14.15% -60.78% -30.84% -39.39% 45.16% 59.47% 50.97%
Free Cash Flow Firm Growth		 9.20% 109.26% 204.08% 171.01% 103.25% -704.75% 127.69% -67.33% -2,145.30% -46.66% -152.39%
Invested Capital Growth		 -29.07% -50.32% -52.73% -75.21% -97.13% -166.29% -185.58% -176.11% -1,011.11% -5.50% -17.25%
Revenue Q/Q Growth		 -30.00% 171.43% -14.04% -14.29% 9.52% 41.30% -38.46% 25.00% -30.00% 28.57% -64.44%
EBITDA Q/Q Growth		 -41.62% 15.14% 26.50% -32.90% -50.60% -74.53% 60.39% 29.48% -14.64% -30.00% 39.74%
EBIT Q/Q Growth		 -41.34% 12.90% 27.87% -33.33% -49.37% -74.11% 59.63% 26.55% -8.12% -32.23% 39.03%
NOPAT Q/Q Growth		 -38.89% 14.81% 22.68% -27.15% -49.37% -71.67% 59.05% 35.58% -21.52% -30.43% 38.19%
Net Income Q/Q Growth		 -31.62% 31.26% 16.59% -34.09% -59.22% -60.90% 53.75% 68.44% -101.53% -61.27% 37.91%
EPS Q/Q Growth		 -30.00% 0.00% 0.00% -25.00% -60.00% -62.50% 53.85% 75.00% -100.00% -66.67% 50.00%
Operating Cash Flow Q/Q Growth		 -114.79% -22.16% 39.36% 41.36% -162.79% -72.07% 50.66% 37.53% -3.39% -27.17% 40.30%
Free Cash Flow Firm Q/Q Growth		 -4.28% 120.90% 262.54% -10.13% -95.23% -3,990.16% 236.50% -87.10% -398.67% -178.96% 51.24%
Invested Capital Q/Q Growth		 -15.10% -28.10% -3.23% -58.04% -90.16% -1,758.48% -24.93% 62.69% -17.85% -92.04% -38.84%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -30,914.29% -9,664.91% -8,263.27% -12,811.90% -17,617.39% -21,760.00% -14,007.50% -7,788.00% -12,754.29% -12,895.56% -21,856.25%
Operating Margin		 -31,052.38% -9,745.61% -8,765.31% -13,002.38% -17,732.61% -21,543.08% -14,335.00% -7,388.00% -12,825.71% -13,011.11% -22,618.75%
EBIT Margin		 -31,047.62% -9,963.16% -8,359.18% -13,002.38% -17,732.61% -21,849.23% -14,335.00% -8,304.00% -12,825.71% -13,191.11% -22,618.75%
Profit (Net Income) Margin		 -30,404.76% -7,700.00% -7,471.43% -11,688.10% -16,991.30% -19,347.69% -14,542.50% -3,672.00% -10,571.43% -13,260.00% -23,156.25%
Tax Burden Percent		 92.74% 78.53% 94.04% 88.37% 92.31% 91.12% 98.63% 41.58% 83.75% 95.37% 99.70%
Interest Burden Percent		 105.60% 98.42% 95.04% 101.72% 103.80% 97.18% 102.86% 106.36% 98.42% 105.41% 102.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -409.32% -149.26% -149.37% -351.79% -786.83% -4,224.95% -6,487.97% -5,009.60% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -405.30% -148.04% -147.64% -348.69% -779.71% -4,213.21% -6,478.77% -5,013.78% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 349.82% 128.03% 126.07% 310.05% 706.62% 4,088.47% 6,381.63% 4,956.36% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -59.51% -21.23% -23.30% -41.74% -80.21% -136.49% -106.34% -53.23% -187.58% -388.69% -3,138.91%
Cash Return on Invested Capital (CROIC)		 -178.99% -149.17% -157.05% -228.96% -347.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -76.65% -28.61% -28.65% -52.01% -92.79% -147.44% -103.14% -67.67% -117.58% -160.24% -294.37%
Return on Assets (ROA)		 -75.06% -22.11% -25.61% -46.75% -88.91% -130.56% -104.63% -29.92% -96.92% -161.08% -301.36%
Return on Common Equity (ROCE)		 -58.69% -20.91% -22.93% -40.99% -78.49% -132.61% -102.65% -52.22% -182.50% -358.64% -907.01%
Return on Equity Simple (ROE_SIMPLE)		 -48.96% 0.00% -55.12% -64.19% -91.92% 0.00% -644.80% -459.60% -821.74% 0.00% 394.30%
Net Operating Profit after Tax (NOPAT)		 -4.56 -3.89 -3.01 -3.82 -5.71 -9.80 -4.01 -2.59 -3.14 -4.10 -2.53
NOPAT Margin		 -21,736.67% -6,821.93% -6,135.71% -9,101.67% -12,412.83% -15,080.15% -10,034.50% -5,171.60% -8,978.00% -9,107.78% -15,833.13%
Net Nonoperating Expense Percent (NNEP)		 -4.03% -1.21% -1.74% -3.10% -7.12% -11.74% -9.20% 4.19% -4.15% -25.35% -27.04%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -95.78% -54.25% - - -416.09% 132.84%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 24,619.05% 6,405.26% 4,677.55% 6,071.43% 11,823.91% 16,701.54% 9,537.50% 5,182.00% 8,797.14% 9,397.78% 15,906.25%
R&D to Revenue		 6,533.33% 3,696.49% 4,187.76% 7,030.95% 5,943.48% 4,923.08% 4,877.50% 2,290.00% 4,105.71% 3,697.78% 6,750.00%
Operating Expenses to Revenue		 31,152.38% 9,840.35% 8,912.24% 13,102.38% 17,747.83% 21,640.00% 14,435.00% 7,488.00% 12,925.71% 13,111.11% 22,718.75%
Earnings before Interest and Taxes (EBIT)		 -6.52 -5.68 -4.10 -5.46 -8.16 -14 -5.73 -4.15 -4.49 -5.94 -3.62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.49 -5.51 -4.05 -5.38 -8.10 -14 -5.60 -3.89 -4.46 -5.80 -3.50
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.67 0.40 0.61 1.10 1.01 2.25 5.68 3.13 5.30 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.70 0.42 0.64 1.18 1.12 2.97 12.89 5.29 40.60 0.00 0.00
Price to Revenue (P/Rev)		 207.15 106.36 132.58 191.91 114.15 106.36 121.78 95.09 81.19 74.20 60.56
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.72 2.36 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 27.96 2.08 45.07 81.99 58.15 57.67 64.38 58.52
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.53 0.43 0.94 -1.75 -0.51
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.05 0.05 0.00 0.00
Financial Leverage		 -0.86 -0.86 -0.85 -0.89 -0.91 -0.97 -0.99 -0.99 -1.05 -1.65 -8.94
Leverage Ratio		 1.04 1.03 1.04 1.07 1.14 1.23 1.35 1.36 1.62 3.14 23.15
Compound Leverage Factor		 1.10 1.01 0.99 1.09 1.18 1.19 1.39 1.45 1.60 3.31 23.78
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 34.78% 30.18% 48.41% 234.21% -102.25%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.94% 26.94% 45.94% 234.21% -102.25%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.84% 3.24% 2.46% 0.00% 0.00%
Preferred Equity to Total Capital		 1.67% 1.81% 1.98% 2.29% 3.05% 6.73% 9.31% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.33% 98.19% 98.02% 97.71% 96.95% 93.27% 55.91% 69.82% 51.59% -134.21% 202.25%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 -0.08 -0.10 -0.12 -0.11
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.23 0.16 0.08 0.02
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.01 -0.01 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 -0.12 -0.14 -0.17 -0.16
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.36 0.34 0.23 0.12 0.02
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.01 -0.01 0.00 0.00
Altman Z-Score		 -6.17 -8.13 -8.66 -10.22 -17.60 -30.21 -35.73 -36.71 -43.79 -71.66 -99.21
Noncontrolling Interest Sharing Ratio		 1.37% 1.48% 1.59% 1.78% 2.15% 2.84% 3.47% 1.90% 2.70% 7.73% 71.10%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.21 26.69 18.05 10.01 4.82 1.68 1.14 1.17 0.75 0.44 0.26
Quick Ratio		 12.69 26.35 17.75 9.85 4.77 1.65 1.11 1.14 0.71 0.42 0.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.13 0.44 1.61 1.45 0.07 -2.69 3.67 0.47 -1.41 -3.94 -1.92
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 50.96 2.64 -7.00 -29.87 -15.50
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -66.88 -16.80 -15.40 -29.96 -19.04
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -66.88 -16.80 -15.40 -29.96 -19.04
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Accounts Receivable Turnover		 0.00 0.09 0.09 0.00 0.00 0.14 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.04 0.07 1.08 1.24 1.53 1.25 1.41 1.58 1.50 1.45 1.35
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 4,293.28 3,956.88 0.00 0.00 2,583.91 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 4,293.28 3,956.88 0.00 0.00 2,583.91 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5.95 4.28 4.14 1.74 0.17 -2.84 -3.54 -1.32 -1.56 -2.99 -4.15
Invested Capital Turnover		 0.02 0.02 0.02 0.04 0.06 0.28 0.65 0.97 -0.27 -0.06 -0.04
Increase / (Decrease) in Invested Capital		 -2.44 -4.33 -4.62 -5.27 -5.78 -7.11 -7.68 -3.06 -1.73 -0.16 -0.61
Enterprise Value (EV)		 -8.07 -18 -9.34 4.73 0.40 9.10 16 12 11 11 8.54
Market Capitalization		 28 15 21 32 22 21 24 19 15 13 8.84
Book Value per Share		 $0.87 $0.79 $0.71 $0.61 $0.45 $0.20 $0.08 $0.12 $0.05 ($0.02) ($0.05)
Tangible Book Value per Share		 $0.83 $0.75 $0.67 $0.57 $0.41 $0.15 $0.04 $0.07 $0.01 ($0.06) ($0.08)
Total Capital		 43 38 35 30 23 10 7.40 8.74 5.64 0.99 -1.91
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 2.57 2.64 2.73 2.31 1.95
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.95 0.28 0.14 0.00 0.00
Net Debt		 -37 -34 -31 -28 -22 -13 -8.37 -7.42 -4.47 -1.67 -0.30
Capital Expenditures (CapEx)		 -0.30 -3.60 -0.03 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.51 0.77 0.47 -2.41 -4.41 -7.17 -7.89 -6.19 -7.14 -7.03 -7.48
Debt-free Net Working Capital (DFNWC)		 38 35 31 26 18 5.90 3.05 3.87 0.06 -3.05 -5.23
Net Working Capital (NWC)		 38 35 31 26 18 5.90 1.43 1.52 -2.53 -5.36 -7.18
Net Nonoperating Expense (NNE)		 1.82 0.50 0.65 1.09 2.11 2.77 1.80 -0.75 0.56 1.87 1.17
Net Nonoperating Obligations (NNO)		 -37 -34 -31 -28 -22 -13 -8.37 -7.42 -4.47 -1.67 -0.30
Total Depreciation and Amortization (D&A)		 0.03 0.17 0.05 0.08 0.05 0.06 0.13 0.26 0.03 0.13 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 1,118.52% 546.10% 301.91% -1,428.40% -2,270.62% -3,547.52% -4,087.56% -3,078.61% -3,757.37% -4,134.71% -5,123.29%
Debt-free Net Working Capital to Revenue		 28,337.04% 24,794.33% 19,950.96% 15,375.15% 9,291.75% 2,922.77% 1,581.87% 1,926.87% 33.16% -1,795.29% -3,584.25%
Net Working Capital to Revenue		 28,337.04% 24,794.33% 19,950.96% 15,375.15% 9,291.75% 2,922.77% 740.93% 755.72% -1,331.58% -3,152.35% -4,919.86%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.13) ($0.09) ($0.08) ($0.10) ($0.16) ($0.26) ($0.12) ($0.03) ($0.06) ($0.10) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 48.08M 48.05M 48.40M 48.41M 48.64M 48.59M 49.46M 52.84M 57.68M 56.02M 70.33M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.10) ($0.16) ($0.26) ($0.12) ($0.03) ($0.06) ($0.10) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 48.08M 48.05M 48.41M 48.41M 48.64M 48.59M 49.46M 52.84M 57.68M 56.02M 70.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 48.08M 48.41M 48.41M 48.67M 48.84M 49.90M 51.28M 57.14M 63.71M 72.29M 76.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.56 -3.89 -2.99 -3.82 -5.74 -9.80 -4.01 -2.59 -3.14 -4.10 -2.53
Normalized NOPAT Margin		 -21,736.67% -6,825.61% -6,102.86% -9,101.67% -12,472.17% -15,080.15% -10,034.50% -5,171.60% -8,978.00% -9,107.78% -15,833.13%
Pre Tax Income Margin		 -32,785.71% -9,805.26% -7,944.90% -13,226.19% -18,406.52% -21,232.31% -14,745.00% -8,832.00% -12,622.86% -13,904.44% -23,225.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -79.64 -23.20 -22.22 -44.97 -29.19
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -55.75 -14.45 -15.56 -31.05 -20.43
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -79.64 -23.20 -22.22 -44.97 -29.19
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -55.75 -14.45 -15.56 -31.05 -20.43
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise four-year look at AIM ImmunoTech's quarterly results (2022–2025), focusing on cash flow, income, and balance sheet signals. The company shows persistent losses and modest revenue, but liquidity has improved at times thanks to asset sales and equity issuances.

  • Investing activities provided cash inflows in multiple recent quarters, driven by sale/maturity of investments: Q2 2024 +$1,055,000; Q3 2024 +$4,920,000; Q4 2024 +$4,026,000; Q1 2025 +$1,045,000.
  • Equity financing injected liquidity across several periods: Q2 2024 +$2,574,000; Q4 2024 +$1,288,000; Q1 2025 +$660,000 (with additional smaller equity raises in earlier quarters).
  • Modest gross profits observed in some quarters (e.g., Q1 2025 gross profit $16,000; Q4 2024 $45,000; Q3 2024 $35,000), suggesting there is a base margin possible when revenue appears.
  • Operating cash burn showed some narrowing in 2025 Q1 versus 2024 Q1 (net cash from continuing operating activities about -$2.36M vs -$4.82M in 2024 Q1), indicating improving cash burn trends.
  • Revenue remains very small and volatile, typically in the tens of thousands per quarter (examples: Q4 2024 $45,000; Q1 2025 $16,000), with no clear, sustained growth pattern.
  • R&D and SG&A expenses are substantial across periods (example: Q1 2025 SG&A $2.545M and R&D $1.080M), contributing to ongoing operating losses.
  • Earnings per share remain negative across periods (for example Q1 2025 Basic EPS -$0.05, Q4 2024 -$0.10, Q3 2024 -$0.16), reflecting persistent losses per share despite small revenue.
  • Net income is consistently negative across quarters, with quarterly losses generally ranging from roughly -$3.7M to -$6.0M (examples: Q1 2025 consolidated net income -$3.705M; Q4 2024 consolidated net income -$5.967M).
  • Cash flow from operating activities is persistently negative across quarters, signaling ongoing cash burn that is not fully offset by financing or investing inflows (examples: Q1 2025 -$2.361M; Q4 2024 -$3.955M; Q3 2024 -$3.110M; Q2 2024 -$3.008M).
05/17/26 11:47 AM ETAI Generated. May Contain Errors.

AIM ImmunoTech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AIM ImmunoTech's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

AIM ImmunoTech's net income appears to be on an upward trend, with a most recent value of -$17.32 million in 2024, falling from -$17.45 million in 2014. The previous period was -$28.96 million in 2023. View AIM ImmunoTech's forecast to see where analysts expect AIM ImmunoTech to go next.

AIM ImmunoTech's total operating income in 2024 was -$19.77 million, based on the following breakdown:
  • Total Gross Profit: $170 thousand
  • Total Operating Expenses: $19.94 million

Over the last 10 years, AIM ImmunoTech's total revenue changed from $197 thousand in 2014 to $170 thousand in 2024, a change of -13.7%.

AIM ImmunoTech's total liabilities were at $9.93 million at the end of 2024, a 8.6% increase from 2023, and a 123.9% increase since 2014.

In the past 10 years, AIM ImmunoTech's cash and equivalents has ranged from $299 thousand in 2018 to $38.50 million in 2020, and is currently $1.70 million as of their latest financial filing in 2024.

Over the last 10 years, AIM ImmunoTech's book value per share changed from 0.13 in 2014 to -0.02 in 2024, a change of -116.6%.



Financial statements for NYSEAMERICAN:AIM last updated on 6/20/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel